Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Current Leases (2019 - 2025)

Protalix BioTherapeutics has reported Current Leases over the past 7 years, most recently at $1.4 million for Q4 2025.

  • Quarterly results put Current Leases at $1.4 million for Q4 2025, down 7.73% from a year ago — trailing twelve months through Dec 2025 was $1.4 million (down 7.73% YoY), and the annual figure for FY2025 was $1.4 million, down 7.73%.
  • Current Leases for Q4 2025 was $1.4 million at Protalix BioTherapeutics, down from $1.4 million in the prior quarter.
  • Over the last five years, Current Leases for PLX hit a ceiling of $1.5 million in Q3 2024 and a floor of $1.0 million in Q3 2022.
  • Median Current Leases over the past 5 years was $1.3 million (2023), compared with a mean of $1.3 million.
  • Biggest five-year swings in Current Leases: fell 19.03% in 2022 and later surged 31.3% in 2023.
  • Protalix BioTherapeutics' Current Leases stood at $1.2 million in 2021, then decreased by 7.37% to $1.1 million in 2022, then increased by 26.03% to $1.4 million in 2023, then increased by 6.46% to $1.5 million in 2024, then fell by 7.73% to $1.4 million in 2025.
  • The last three reported values for Current Leases were $1.4 million (Q4 2025), $1.4 million (Q3 2025), and $1.5 million (Q2 2025) per Business Quant data.